Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration

Eye

Volumn 21, Issue 3, 2007, Pages 387-394

  Jonas, J B ^a   Spandau, U H ^a   Kamppeter, B A ^a   Harder, B ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TRIAMCINOLONE ACETONIDE;

AGED; ARTICLE; CASE STUDY; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; RETINA MACULA AGE RELATED DEGENERATION; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL SYSTEM EXAMINATION;

EID: 33847688118     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6702222     Document Type: Article

References (47)

1. Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc 1979; 77: 171-180.
2. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of tramcinolone acetonide. Am J Ophthalmol 1980; 90: 810-816.
3. Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferation with intravitreal corticosteroid. Am J Ophthalmol 1980; 89: 131-136.
4. Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 1985; 103: 708-711.
5. Antoszyk AN, Gottlieb JL, Machemer R, Hatchell DL. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefes Arch Clin Exp Ophthalmol 1993; 231: 34-40.
6. Machemer R. Five cases in which a depot steroid (hydrocortisone acetate and methylprednisolone acetate) was injected into the eye. Retina 1996; 16: 166-167.
7. Danis RP, Bingaman DP, Yang Y, Ladd B. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996; 103: 2099-2104.
8. Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust NZ J Ophthalmol 1995; 23: 293-298.
9. Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust NZ J Ophthalmol 1998; 26: 277-281.
10. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000; 20: 244-250.
11. Jonas JB, Kreissig I, Degenring RF. Repeated intravitreal injections of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration. Graef Arch Clin Exp Ophthalmol 2002; 240: 873-874.
12. Ranson NT, Danis RP, Ciulla TA, Pratt L. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br J Ophthalmol 2002; 86: 527-529.
13. Penfold PL. Intravitreal triamcinolone in recurrence of choroidal neovascularisation. Br J Ophthalmol 2002; 86: 600-601.
14. Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor HB, Chua W et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: One-year results. Arch Ophthalmol 2003; 121: 667-873.
15. Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R. Intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Br J Ophthalmol 2003; 87: 462-468.
16. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003; 110: 1517-1525.
17. Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF. Intravitreal re-injection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 2004; 122: 218-222.
18. Jonas JB, Degenring RF, Kreissig I, Friedemann T, Akkoyun I. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative non-randomized study. Eye 2005; 19: 163-170.
19. Jonas JB, Kreissig I, Degenring RF. Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age-related macular degeneration. Br J Ophthalmol 2004; 88: 1557-1562.
20. Jonas JB, Spandau UH, Harder B, Vossmerbaeumer U, Kamppeter BA. Inter-eye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularisation after unilateral intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2005; 139: 1073-1079.
21. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative and angiogenic diseases. Prog Ret Eye Res 2005; 5: 587-611.
22. Jonas JB, Hayler JK, Söfker A, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001; 131: 468-471.
23. Jonas JB, Söfker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular oedema. Am J Ophthalmol 2001; 132: 425-427.
24. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E et al. Intravitreal triamcinolone for refractory diabetic macular oedema. Ophthalmology 2002; 109: 920-927.
25. Jonas JB, Hayler JK, Söfker A, Panda-Jonas S. Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. J Glaucoma 2001; 10: 284-287.
26. Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol 2002; 86: 247-248.
27. Jonas JB, Kreissig I, Degenring RF. Endophthalmitis after intravitreal injection of triamcinolone acetonide. Arch Ophthalmol 2003; 121: 1663-1664.
28. Spandau UHM, Derse M, Schmitz-Valckenberg P, Papoulis C, Sagstetter BU, Stiefvater KH et al. Measurement of triamcinolone acetonide concentration after filtering of solvent agent. Am J Ophthalmol 2005; 139: 712-713.
29. Spandau U, Sauder G, Schubert U, Hammes HP, Jonas JB. Effect of triamcinolone acetonide on proliferation of retinal endothelial cells in vitro and in vivo. Br J Ophthalmol 2005; 89: 745-747.
30. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005; 112: 301-304.
31. Smithen LM, Spaide RF. Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. Am J Ophthalmol 2004; 138: 884-885.
32. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularization in age related macular degeneration. Br J Ophthalmol 2004; 88: 344-347.
33. Arevalo JF, Garcia RA, Mendoza AJ. Indocyanine green-mediated photothrombosis with intravitreal triamcinolone acetonide for subfoveal choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2005 May 20; [E-pub ahead of print].
34. Augustin AJ, Schmidt-Erfuhrt U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularisation due to age-related macular degeneration. Ophthlmology 2005, in press.
35. Augustin AJ, Schmidt-Erfuhrt U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularisation in age-related macular degeneration. Am J Ophthalmol 2005, in press.
36. Schlotzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfuhrt U. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 2002; 240: 748-757.
37. Gragoudas ES, Adamis Ap, Cunningham Jr ET, Feinsold M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-2816.
38. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger DS, Luna SP et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: Twelve-month clinical outcomes. Ophthalmology 2003; 110: 2372-2383.
39. Husain D, Kim I, Gauthier D, Luna AM, Tsilimbaris MK, Ezra E et al. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 2005; 123: 509-516.
40. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two year results of a randomized clinical trial including lesions with occultwith no classic choroidal neovascularization - Verteporfin in Photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541-560.
41. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust NZ J Ophthalmol 1999; 27: 431-432.
42. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005; 112: 593-598.
43. Jonas JB, Degenring R, Kamppeter B, Kreissig I, Akkoyun I. Duration of the effect of intravitreal triamcinolone acetonide as treatment of diffuse diabetic macular oedema. Am J Ophthalmol 2004; 138: 158-160.
44. Sutter FK, Gillies MC. Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol 2003; 87: 972-974.
45. Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003; 121: 1279-1282.
46. Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W et al. Safety of an intravitreal injection of triamcinolone: Results from a randomized clinical trial. Arch Ophthalmol 2004; 122: 336-340.
47. Kaiser PK. Verteprofin therapy in combination with triamcinolone: published studies investigating a potential synergistic effect. Curr Med Res Opinion 2005; 5: 705-706.